Anzeige
Mehr »
Freitag, 12.06.2026 - Börsentäglich über 12.000 News
BTQ 73x. Kommt jetzt Delta?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41984 | ISIN: CNE100006XS6 | Ticker-Symbol: 0BO
Stuttgart
11.06.26 | 21:56
5,600 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
FTSE China 50
1-Jahres-Chart
JIANGSU HENGRUI PHARMACEUTICALS CO LTD Chart 1 Jahr
5-Tage-Chart
JIANGSU HENGRUI PHARMACEUTICALS CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
5,6505,75011.06.
5,5505,75011.06.

Aktuelle News zur JIANGSU HENGRUI PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoHengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types304SHANGHAI and CHICAGO, June 8, 2026 /PRNewswire/ -- The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 29 to June 2 (local time). As one of the...
► Artikel lesen
JIANGSU HENGRUI PHARMACEUTICALS Aktie jetzt für 0€ handeln
SaKailera Therapeutics, Inc.: Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 20264
04.06.HENGRUI PHARMA (01276): NEXT DAY DISCLOSURE RETURN3
03.06.CSPC PHARMA Falls 4%, HENGRUI PHARMA Slumps 7%; Citi Says Low Chance of US Bill to Curb Investment in China Biotech Passing, Sees Buying Opportunity in Pharma Sector5
28.05.HENGRUI PHARMA (01276): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE APPROVAL FOR DRUG REGISTRATION-
15.05.HENGRUI PHARMA's RSS0393 Lotion Approved for Clinical Trials1
14.05.HENGRUI PHARMA's SHR-3079 Injection Approved for Clinical Trials1
13.05.Bristol Myers Squibb And Hengrui Pharma Enter $15.2 Billion Global Collaboration To Advance 13 Early-Stage Programs5
12.05.Bristol Myers, Hengrui Pharma Team Up in Global Drug Research Pact That Could Top $15B2
12.05.BMO bestätigt Rating für Bristol-Myers Squibb nach Milliardendeal mit Hengrui20
12.05.BMO reiterates Bristol-Myers Squibb stock rating on Hengrui deal4
12.05.BMS and Hengrui forge $15.2bn alliance for early-stage drugs8
12.05.Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion7
12.05. BMS, Hengrui Pharma Partner to Advance Early Stage Programs3
12.05.China's Hengrui Jumps After Inking USD15 Billion Innovative Drug Deal With BMS4
12.05.Bristol Myers and China's Hengrui Pharma ink a licensing deal worth up to $15.2B7
12.05.BMS signs $15.2bn R&D alliance with China's Hengrui4
12.05.Bristol Myers Squibb Strikes $15.2 Billion Drug Development Deal With Hengrui Pharma3
12.05.Bristol Myers Squibb inks $15B biobucks deal to bag Hengrui assets, tap China's R&D speed8
12.05.Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology451Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide Agreements include...
► Artikel lesen
Weiter >>
67 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1